NCT00456807View on ClinicalTrials.gov

Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

Placebo

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

BIOLOGICAL

Cervarix TM

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Trial Locations (2)

1007 MB

GSK Investigational Site, Amsterdam

2625 AD

GSK Investigational Site, Delft

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY